ONCOLYTICS BIOTECH INC (ONCY) Stock News

USA - NASDAQ:ONCY - CA6823108759 - Common Stock

1.25 USD

-0.02 (-1.57%)

Last: 9/24/2025, 8:00:02 PM

1.23 USD

-0.02 (-1.6%)

After Hours: 9/24/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ONCY Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

2 months ago - By: Benzinga

What to Expect from Oncolytics Biotech's Earnings

10 days ago - By: Benzinga - Mentions: AHG COCP CHEK HSDT ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

17 days ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

23 days ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

a month ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

a month ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

2 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

2 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

2 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

2 months ago - By: Oncolytics Biotech® Inc.

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

2 months ago - By: Oncolytics Biotech® Inc.

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential